Vaccine value-volume split

Because Big Four control 70% value, programs depend on LMIC volume producers. High-income firms dominate revenue with costly, lower-volume products while global immunization hinges on cheaper, high-throughput suppliers. — This divergence drives policy on procurement, tiered pricing, and market-shaping by Gavi/UNICEF, and conditions debates on affordability and access.